GLP-1

꾸준한114 이야기18 출처마지막 업데이트: 23 hours ago

최신 뉴스

건강

23 hours agoAI 요약

GLP-1減重藥物在職業體育中的爭議：性能增強還是健康管理？

網球名將塞雷娜·威廉姆斯公開使用GLP-1減重藥物引發討論。專家探討此類藥物是否具備提升運動表現的潛力，以及其對運動員健康、體育公平性及青少年榜樣效應的影響。

Hims & Hers CEO Andrew Dudum Defends Company Against FTC Lawsuit

Hims & Hers CEO Andrew Dudum defended his company against an FTC lawsuit alleging improper data sharing and deceptive subscription practices. Dudum characterized the legal action as a misunderstanding of the company's efforts to disrupt traditional healthcare.

Weight-Loss Meds Act As 'Regressive Tax On Being Thin' For Lower Earners

An analysis by consultancy Baringa reveals that GLP-1 weight-loss medications act as a regressive tax, as individuals need a discretionary income of nearly £100,000 to save money after covering the drug's £1,200 annual cost.

GLP-1'den sonra yeni trend: Beynin uyanıklık kimyasalı oreksin

GLP-1 ilaçlarının ardından ilaç sektörü oreksin kimyasallarını taklit eden yeni tedavilere yöneldi. Takeda'nın narkolepsi ilacı FDA'dan onay alırken, Eli Lilly Centessa'yı satın aldı.

Eli Lilly and Novo Nordisk Face Diverging Fortunes in the Booming GLP-1 Market

Eli Lilly and Novo Nordisk both beat Q2 estimates and raised outlooks, but Wall Street rewarded Lilly while punishing Novo over pipeline and market share concerns in the $100B+ obesity drug sector.

MHRA'dan Orforglipron'a Kilo Yönetimi ve Tip 2 Diyabet için Onay

İngiltere'nin ilaç denetim kurumu MHRA, orforglipron adlı GLP-1 tabletini kilo yönetimi ve tip 2 diyabet tedavisi için onayladı. Avrupa'da ilk onay veren ülke oldu.

Nearly 200 Deaths Linked to GLP-1 Weight-Loss Drugs in the UK

Nearly 200 deaths and over 150,000 adverse reactions have been linked to anti-obesity drugs Mounjaro, Wegovy, Ozempic, and Saxenda in the UK, according to data from the MHRA Yellow Card scheme.

Bank of America CEO'su Moynihan: Kilo verme ilaçlarına yılda 250 milyon dolardan fazla ödüyoruz

Bank of America CEO'su Brian Moynihan, bankanın 211 bin çalışanı için sağlanan sağlık sigortası kapsamında GLP-1 kilo verme ilaçlarına yıllık 250 milyon dolardan fazla harcadıklarını ve bunun iyi bir yatırım olduğunu belirtti.

Eli Lilly reports strong Q2 results driven by GLP-1 drugs, raises full-year guidance

Eli Lilly reported better-than-expected Q2 2026 results with revenue up 48% to $22.97 billion, driven by its GLP-1 portfolio including Zepbound and Mounjaro, prompting the company to raise its full-year revenue guidance.

Bank of America spends over $250M annually on GLP-1 weight loss drugs for staff

Bank of America spends over $250 million annually covering GLP-1 weight loss drugs for employees, accounting for roughly 13% of its $2 billion healthcare budget, CEO Brian Moynihan told CNBC.

CNBC US Markets

2 min read

Novo Nordisk shares drop 6% after updated guidance and Q2 sales report

개발 중

Business·8/5/2026AI 요약

Novo Nordisk shares drop 6% after updated guidance and Q2 sales report

U.S.-traded shares of Novo Nordisk fell 6% Tuesday after the Danish drugmaker issued updated 2026 guidance and reported second-quarter financial metrics, citing intensifying competition and lower U.S. prices.

Dermatologists Report Increased Hair Loss Among GLP-1 Drug Users

Dermatologists in India report a rise in hair loss, often telogen effluvium, among GLP-1 weight-loss drug users, particularly those experiencing rapid weight reduction without medical supervision. Nutritional deficiencies and metabolic stress are cited as causes, with a Saudi Arabian study finding 70.4% of users reported shedding.

Mini Fridges Become New Bathroom Must-Have for Beauty and Wellness Products

Growing demand for mini fridges for beauty products and GLP-1 medication is reshaping homes, driven by the wellness industry and weight-loss drugs. This trend spans luxury to budget markets, despite dermatological skepticism for most skincare products.

Guardian Business

3 min read

Proteinmaxxing Trend and GLP-1 Drugs Drive Up Whey Protein Costs, Threatening Infant Formula Prices

개발 중

Business·8/1/2026AI 요약

Proteinmaxxing Trend and GLP-1 Drugs Drive Up Whey Protein Costs, Threatening Infant Formula Prices

The "proteinmaxxing" trend and GLP-1 weight-loss medications are driving up demand for whey protein, a vital ingredient in infant formula. This has led to a 4.8% increase in UK formula prices, raising concerns about affordability for families and prompting calls for government-imposed price or profit caps.

Guardian Business

3 min read

개발 중

Business·8/1/2026AI 요약

Retail Giants Bet on GLP-1 Weight-Loss Drugs for Customer Loyalty and Market Share

US retail giants like Walmart, Costco, CVS, and Amazon are leveraging direct-to-consumer GLP-1 weight-loss drug programs to acquire long-term customer relationships, as employers increasingly drop coverage. This strategy aims to drive loyalty and cross-selling opportunities.

A Personal Journey: Embracing Strength Training Over Wedding Diet Pressure

A woman recounts her struggle with body image and unhealthy dieting before her wedding. She later finds liberation and physical strength by adopting a "bulking" regimen, focusing on muscle gain and progressive overload, challenging ingrained societal beauty standards despite internal anxieties.

Guardian International

10 min read

Avustralya'dan zayıflama iğnesi uyarısı: Körlüğe yol açabilir

긴급

건강·7/24/2026AI 요약

Avustralya'dan zayıflama iğnesi uyarısı: Körlüğe yol açabilir

Avustralya Şifalı Ürünler İdaresi (TGA), Tip-2 diyabet ve obezite tedavisinde kullanılan GLP-1 ilaçlarının nadir görülen "arteritik olmayan anterior iskemik optik nöropati (NAION)" hastalığına yol açabileceği konusunda uyardı. NAION'un körlük dahil kalıcı görme bozukluğuna neden olabileceği belirtilirken, kullanıcıların görme kaybı yaşamaları halinde ilacı bırakıp acilen sağlık kuruluşuna başvurması gerektiği vurgulandı. TGA, 36 vaka tespit etti.

Avustralya TGA'dan Diyabet ve Obezite İlaçları Hakkında Görme Kaybı Uyarısı

Avustralya Şifalı Ürünler İdaresi (TGA), Tip-2 diyabet ve obezite tedavisinde kullanılan GLP-1 ilaçlarının nadir görülen "arteritik olmayan anterior iskemik optik nöropati (NAION)" hastalığına yol açabileceği konusunda uyardı. NAION, kalıcı görme bozukluğuna ve körlüğe neden olabilir; TGA, bu ilaçlarla bağlantılı 36 NAION vakası tespit edildiğini belirtti.

Australia warns on Ozempic, Mounjaro eye disorder risk

Australia's Therapeutic Goods Administration (TGA) has warned about a "rare but severe" eye disorder, non-arteritic anterior ischaemic optic neuropathy (NAION), linked to type 2 diabetes and obesity treatments like Ozempic and Mounjaro. The warning, based on 36 reported cases, advises patients to seek urgent medical attention for sudden vision loss but not to stop treatment without consulting a doctor.

Australian News Briefing: Christian Brothers Compensation, Trade Tariffs, and Climate Concerns

A news briefing highlights the Christian Brothers' agreement to compensate abuse survivors, new US trade tariffs on Australian exports, and domestic concerns over an impending El Niño summer, alongside other headlines including a Socceroos star's alleged drug test and airport advertising disputes.

Regulator Warns of Rare Eye Disorder Risk with GLP-1 Diabetes and Obesity Drugs

Australia's TGA has issued a safety warning for GLP-1 drugs like Ozempic, Mounjaro, and Wegovy, linking them to non-arteritic anterior ischaemic optic neuropathy (NAION), a rare eye disorder causing potential permanent vision loss. Experts advise caution but not panic, stressing consultation with prescribers.

GLP-1 Grubu İlaçların Saç Dökülmesi Riski Ortaya Çıktı

Pennsylvania Üniversitesi araştırmacıları, Ozempic ve Wegovy gibi GLP-1 ilaçlarının saç dökülmesi riskini SGLT-2 ve DPP-4 inhibitörlerine kıyasla daha yüksek buldu. Çalışma, hızlı kilo kaybı ve besin eksikliğinin geçici saç dökülmesine yol açabileceğini belirtiyor.

Galderma CEO'su: Hızlı Kilo Kaybı Sonrası Yüz Estetiği Talebi Artıyor

İsviçre merkezli Galderma'nın CEO'su Flemming Ørnskov, GLP-1 ilaçları kaynaklı hızlı kilo kaybı sonrası yüzde oluşan sarkma ve hacim kaybına yönelik estetik tedavilere talebin arttığını belirtti. Şirketin ABD satışları yüzde 32 artarken, bu durumun önemli bir fırsat olduğu vurgulandı.

Weight-Loss Drugs Create "Significant Opportunity" for Aesthetics Company Galderma

Galderma CEO Flemming Ørnskov stated that the increased use of weight-loss drugs like Ozempic and Wegovy presents a "significant opportunity" for the aesthetics company, particularly in mitigating facial sagging. The company reported nearly 25% sales growth, with U.S. growth outpacing other regions at 32%.

CNBC World

1 min read